Maze Therapeutics Inc.

NASDAQ: MAZE · Real-Time Price · USD
8.48
0.10 (1.19%)
At close: Apr 29, 2025, 11:24 AM
1.19%
Bid 8.36
Market Cap 371.61M
Revenue (ttm) 2.5M
Net Income (ttm) -105.66M
EPS (ttm) 0.08
PE Ratio (ttm) 106.06
Forward PE n/a
Analyst Buy
Ask 8.54
Volume 39,024
Avg. Volume (20D) 301,703
Open 8.52
Previous Close 8.38
Day's Range 8.05 - 8.52
52-Week Range 6.71 - 17.00
Beta 0.00

About MAZE

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of ...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2025
Employees 125
Stock Exchange NASDAQ
Ticker Symbol MAZE
Full Company Profile

Advertisement

Analyst Forecast

According to 3 analyst ratings, the average rating for MAZE stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 229.99% from the latest price.

Stock Forecasts
3 weeks ago
-10.08%
Maze Therapeutics shares are trading lower on poss... Unlock content with Pro Subscription
2 months ago
-2.31%
Maze Therapeutics shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and announced a price target of $30. Additionally, Leerink Partners initiated coverage on the stock with an Outperform rating and announced a price target of $28.